Mentari Therapeutics, Inc. filed a Form 8-K on November 20, 2026, disclosing changes to its independent registered public accounting firm following the November 6, 2026 completion of its merger with the former InMed Pharmaceuticals Inc.

Key Highlights

  • Two auditors dismissed: CBIZ CPAs P.C. and Ernst & Young LLP were each dismissed as independent registered public accounting firms on November 17, 2026, with both dismissals approved by the Audit Committee.
  • Deloitte engaged: Deloitte & Touche LLP was engaged on November 19, 2026, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
  • Going concern notes: Both CBIZ's reports on InMed (fiscal years ended June 30, 2026 and 2025) and EY's report on Mentari (period from June 13, 2025 inception to December 31, 2025) included explanatory paragraphs stating that substantial doubt exists about the respective entity's ability to continue as a going concern.
  • No disagreements reported: The filing states there were no disagreements with either CBIZ or EY on accounting principles, financial statement disclosure, or auditing scope, and no "reportable events" as defined under Regulation S-K.
  • Reverse recapitalization: The merger was accounted for as a reverse recapitalization, with Mentari treated as the accounting acquirer, making Mentari's historical financial statements the historical financial statements of the combined company.
  • Auditor letters filed: Letters from both CBIZ and EY to the SEC, each dated November 19, 2026, are filed as Exhibits 16.1 and 16.2, respectively.

Auditor Transition at Mentari Therapeutics Following Merger Closing

According to the filing, Mentari Therapeutics, Inc. (NASDAQ:MTRI) completed its business combination on November 6, 2026, when InMed Pharmaceuticals Inc. merged with Mentari Therapeutics, Inc., a Delaware corporation, through a two-step merger structure. For accounting purposes, the company disclosed that the transaction was treated as a reverse recapitalization with Mentari as the accounting acquirer, meaning Mentari's historical financial statements became the historical financial statements of the combined company.

The filing reports that CBIZ CPAs P.C. had served as InMed's independent registered public accounting firm prior to the merger. On November 17, 2026, the Audit Committee approved CBIZ's dismissal. The filing states that CBIZ's audit reports for InMed's fiscal years ended June 30, 2026 and 2025 did not contain adverse opinions or disclaimers of opinion, except for an explanatory paragraph noting substantial doubt about InMed's ability to continue as a going concern. Similarly, Ernst & Young LLP, which had served as Mentari's auditor, was dismissed on the same date. EY's report covering the period from June 13, 2025 (inception) to December 31, 2025 likewise contained only a going concern explanatory paragraph, with no adverse opinion or reportable events disclosed.

The company disclosed that on November 19, 2026, the Audit Committee approved the engagement of Deloitte & Touche LLP for the fiscal year ending December 31, 2026. The filing states that none of InMed, Mentari, or the Company consulted with Deloitte regarding accounting principles, audit opinion types, or any matter that was the subject of a disagreement or reportable event during the covered periods. Pursuant to SEC requirements, both CBIZ and EY furnished letters to the SEC dated November 19, 2026, confirming their agreement or disagreement with the Company's disclosures; these are filed as Exhibits 16.1 and 16.2.

What Was Disclosed

Mentari Therapeutics disclosed the dismissal of CBIZ CPAs P.C. and Ernst & Young LLP as auditors on November 17, 2026, and the engagement of Deloitte & Touche LLP on November 19, 2026, all approved by the Audit Committee following the November 6, 2026 merger closing.